John Libbey Eurotext

Hématologie

MENU

Pathophysiology and abnormalities of haemostasis in intensive care patients with COVID-19 Ahead of print

Figures

  • Figure 1

Tables

Authors
1 Service d′hématologie biologique, Hôpital Lariboisière, AP-HP.Nord, Université de Paris, Paris, France; EA3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
2 Service d′hématologie biologique, Hôpital Lariboisière, AP-HP.Nord, Université de Paris, Paris, France; UMR-S1140 Inserm, innovative therapies in haemostasis, Université de Paris, Paris, France
3 Service d′hématologie biologique, Hôpital Lariboisière, AP-HP.Nord, Université de Paris, Paris, France
4 Service d′hématologie biologique, Hôpital Lariboisière, AP-HP.Nord, University of Paris, Paris, France; UMR-S1140 Inserm, innovative therapies in haemostasis, University of Paris, Paris, France
* Off-prints

Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2) that has now spread to all continents. About 5–10% of COVID-19 patients are admitted to an intensive care unit and require mechanical ventilation. Critically-ill COVID-19 patients are prone to developing hypoxia, excessive inflammation and frequent thrombotic manifestations affecting both macrocirculation and microcirculation.